The metastatic sites profiled for these patients were pleural effusions (ER/PR+, HER2-) (patient 1 in Table 1) (Fig. 4A and B), (ER+, PR/HER2-) (patient 15 in Table 1) (Fig. 4C and D). Here, ERBB2 is linked to Pleural effusion.